ANI Pharmaceuticals Completes Acquisition of Novitium Pharma
ANI Pharmaceuticals, Inc. has successfully completed the acquisition of Novitium Pharma, a New-Jersey-based pharmaceutical company.
Based in Baudette, Minnesota, ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals.
With the combined forces of Novitium and ANI Pharmaceuticals, the company is looking forward to expanded R&D capabilities. The acquisition brings aboard a world-class R&D engine in the generic and 505(b)(2) sectors as well as a highly-compliant US based manufacturing facility. With these additions, they are well positioned for sustainable growth.
“ANI is thrilled to welcome the expertise and leadership of Novitium’s founders, Samy Shanmugam, Chad Gassert and Vijay Thorappadi, along with over 100 talented and dedicated employees, who have joined the ANI team. Our robust product pipeline includes several more CGT and 505 (b)(2) candidates and will be further expanded to maximize the value of our bolstered R&D engine,” said Nikhil Lalwani, President and Chief Executive Officer of ANI.
Are you developing new pharmaceuticals for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.